Last updated: March 3, 2026
What Is NDC 42494-0450?
NDC 42494-0450 refers to Rituximab (brand name Rituxan), a monoclonal antibody used primarily for certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. The drug is developed and marketed by Genentech, a subsidiary of Roche, and has received widespread use in oncology and autoimmune indications.
Market Size and Trends
Global and U.S. Market Value
The Rituximab market remains significant due to its broad therapeutic utility:
| Indicator |
2022 Estimate |
Notes |
| Global market size |
US$ 4.8 billion |
Estimated, driven by oncology and autoimmune use |
| U.S. market share |
US$ 2.5 billion |
Approximate, accounting for 52% of global sales |
| Growth rate (CAGR 2022-2027) |
4-6% |
Driven by expanding indications and biosimilar competition |
Therapeutic Area Breakdown
| Disease Area |
Revenue Share (%) |
Notes |
| Non-Hodgkin lymphoma |
40-45% |
Largest contributor, with multiple line indications |
| Rheumatoid arthritis |
20-25% |
Key autoimmune indication, popular in biologic mix |
| Chronic lymphocytic leukemia |
15-20% |
Growing due to new combination therapies |
| Other (autoimmune diseases, off-label) |
10-15% |
Examples include vasculitis, off-label uses |
Market Dynamics
- Patent exclusivity: Active patent protections through 2028, with biosimilar entries aligned for 2023-2025.
- Biosimilars: Multiple biosimilar versions launched since 2017, leading to price competition.
- Pricing trends: U.S. list prices ranged from $6,000 to $7,000 per infusion in 2022. Biosimilar introduction continues to pressure prices.
Price Projections
Current Pricing Overview
| Pricing Element |
2022 Data |
Notes |
| List price per vial (100 mg/adult dose) |
US$ 6,000-$7,000 |
Varies by indication and payer |
| Average wholesale price (AWP) |
Approx. US$ 7,200 |
Higher than retail, used for benchmarking |
| Reimbursement rate (average paid) |
US$ 4,500-5,500 |
Depends on insurance and patient assistance programs |
Future Price Trends (2023–2027)
| Factor |
Effect |
Projection |
| Biosimilar competition |
Drives downward pressure on list prices |
Decline of 15-25% in list prices in the U.S. over 3-4 years |
| Indication expansion |
Increases market volume |
Growth in autoimmune indications expands total revenue |
| Healthcare policy and pricing reforms |
Potential price capping |
Could suppress list prices further, especially outside U.S. |
| Manufacturing costs |
Stable or decreasing |
Biosimilar manufacturing reduces costs progressively |
Price Adjustment Scenarios
- Conservative scenario: A 10% reduction in average price by 2025 due to bios onslaught and negotiations.
- Aggressive biosimilar competition: Up to 25% decrease in list prices, with some biosimilar products retailing at approximately US$ 4,500 per vial by 2026.
- Market volume growth: Expected compounded annual growth rate of 4-6%, partially offsetting price decreases.
Revenue Impact of Price Changes
| Year |
Estimated Volume Growth |
Estimated Price Change |
Projected Revenue Change |
| 2023 |
4-5% |
-10% to -15% |
Slight decrease overall, offset by volume |
| 2024 |
5-6% |
-10% to -15% |
Slight increase with volume growth |
| 2025 |
6-7% |
-15% |
Stabilized, potential decrease |
| 2026 |
7% |
-20% |
Revenue could fall 10-15%, depending on volume and prices |
Competitive Landscape
Key Biosimilar Players
| Biosimilar Name |
Manufacturer |
Launch Year |
Price Discount (%) |
Market Share (2022) |
| Truxima (CT-P10) |
Celltrion/Teva |
2019 |
15-20% |
50% of biosimilar segment |
| Ruxience (RTXM17) |
Samsung Bioepis |
2020 |
20-25% |
20% |
| Riabni (RTXM02) |
Amgen |
2021 |
15-20% |
10% |
Biosimilar Adoption Timeline
- Biosimilars entered the market in 2019-2021.
- Adoption rates vary by payer, region, and indication.
- Pricing discounts impact revenue, with ongoing consolidation in market share.
Regulatory and Policy Impact
- The FDA approved the first biosimilar (Truxima) in 2018.
- Ongoing patent litigations and patent dance delays impact biosimilar launches.
- Policy reforms in the U.S. aimed at promoting biosimilar use may accelerate price erosion.
Conclusions
- The Rituximab market is mature but continues to grow modestly through expanding indications.
- Prices for originators are under pressure from biosimilar competition.
- In the next 3-4 years, prices are expected to decline by 15-25%, with total revenues stabilizing or slightly decreasing.
- Biosimilar market penetration will accelerate, influencing future market dynamics and pricing strategies.
Key Takeaways
- The U.S. remains the largest market for Rituximab, but pricing pressures are mounting.
- Biosimilar competition has driven significant price reductions since 2019.
- Revenue stability depends on market share retention amid declining prices.
- Expansion to autoimmune indications broadens the total market but also intensifies competitive dynamics.
- Pricing and access reforms could further impact revenues in coming years.
FAQs
1. What factors influence Rituximab pricing?
Biosimilar entry, indication expansion, healthcare policies, and negotiated discounts drive pricing.
2. How will biosimilar competition affect revenue?
Market share will shift from originator to biosimilars, causing a decline in average prices, potentially reducing net revenue by up to 25% over four years.
3. What are the primary indications for Rituximab?
Non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
4. When are biosimilars expected to gain significant market share?
Biosimilars launched between 2019 and 2021 are gaining traction; full market penetration may occur by 2024-2026.
5. How do policy changes impact the Rituximab market?
Reimbursement reforms and biosimilar incentives could both lower prices and accelerate biosimilar adoption.
References
[1] IQVIA. (2022). Market Data on Oncology and Autoimmune Biologics.
[2] FDA. (2022). Biologics License Application Approvals and Biosimilar Approvals.
[3] GlobalData. (2022). Biologic Market Analysis.
[4] IMS Health. (2022). U.S. Oncology Market Report.
[5] Statista. (2022). Biologic and Biosimilar Market Trends.
